Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Journal of the Advanced Practitioner in Oncology|June 6, 2022
Clinically Relevant Drug Interactions in the Cancer SettingDavid DeRemer
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|March 22, 2013
Brentuximab vedotin: an anti-CD30 antibody-drug conjugateAmber M Bradley, Meghan Devine, David DeRemer
Expert Review of Pharmacoeconomics & Outcomes Research|May 3, 2021
Cost-effectiveness and drug wastage of immunotherapeutic agents for hematologic malignancies: a systematic reviewZiyan Chen, Yue Cheng, David DeRemer, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 16, 2018
Randomized, Placebo-Controlled, Phase III Trial of Fosaprepitant, Ondansetron, Dexamethasone (FOND) Versus FOND Plus Olanzapine (FOND-O) for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients with Hematologic Malignancies Receiving Highly Emetogenic Chemotherapy and Hematopoietic Cell Transplantation Regimens: The FOND-O TrialAmber B Clemmons, Julianne Orr, Benjamin Andrick, et al.
Journal of Oncology|May 10, 2012
Plerixafor Salvage Is Safe and Effective in Hard-to-Mobilize Patients Undergoing Chemotherapy and Filgrastim-Based Peripheral Blood Progenitor Cell MobilizationFarrukh T Awan, S Thomas Kochuparambil, David Deremer, et al.
Journal of the Advanced Practitioner in Oncology|June 29, 2019
Collaboration Leads to Oral Chemotherapy EducationAshley E Glode, Lisa Holle, Josh Nubla, et al.
Acta Haematologica|November 13, 2010
Acute myelogenous leukemia patients are at low risk for invasive fungal infections after high-dose cytarabine consolidations and thus do not require prophylaxisGrant Lewis, Patricia Hall, Nihal Eisa, et al.
JCO Oncology Practice|March 12, 2021
Immunotherapy Management in Special Cancer Patient PopulationsBrian H Ramnaraign, Jonathan A Chatzkel, Zeina A Al-Mansour, et al.
Journal of Cardiovascular Pharmacology|October 16, 2021
Cardiometabolic Consequences of Targeted Anticancer TherapiesAvirup Guha, Yan Gong, David DeRemer, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 18, 2012
Intermediate-dose versus low-dose cyclophosphamide and granulocyte colony-stimulating factor for peripheral blood stem cell mobilization in patients with multiple myeloma treated with novel induction therapiesMehdi Hamadani, S Thomas Kochuparambil, Salman Osman, et al.
Pageof 2